NDAORALTABLET
Approved
Jan 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANADROL-50 (oxymetholone) is an oral anabolic steroid approved in 1972 for treating certain anemias and muscle-wasting conditions. The mechanism of action involves androgenic and anabolic effects that stimulate red blood cell production and protein synthesis. It is primarily used in niche therapeutic settings where erythropoiesis stimulation is clinically indicated.
LOE Approaching
Declining market with moderate competitive pressure (30%) suggests small, defensive teams focused on managed care and specialty pharmacy relationships rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ANADROL-50 offers limited career growth opportunities and small team environments focused on defensive commercial strategies and regulatory maintenance. This role is best suited for professionals seeking stability in niche specialty markets rather than dynamic product growth or innovation.
Specialty Pharmacy ManagerCompliance Officer
Worked on ANADROL-50 at Pharmobedient? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.